Literature DB >> 15237077

Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.

Tsung-Ung W Woo1, John P Walsh, Francine M Benes.   

Abstract

BACKGROUND: Disturbances of gamma-aminobutyric acid interneurons in the cerebral cortex contribute to the pathophysiology of schizophrenia and bipolar disorder. The activity of these neurons is, in turn, modulated by glutamatergic inputs furnished by pyramidal neurons.
OBJECTIVE: To test the hypothesis that glutamatergic inputs onto gamma-aminobutyric acid interneurons via the N-methyl-d-aspartate (NMDA) receptor are altered in the anterior cingulate cortex in schizophrenia and bipolar disorder.
DESIGN: A double in situ hybridization technique was used to simultaneously label the messenger RNA (mRNA) for the NMDA NR(2A) subunit with (35)sulfur and the mRNA for the 67-kDa isoform of the gamma-aminobutyric acid synthesizing enzyme glutamic acid decarboxylase (GAD(67)) with digoxigenin.
SETTING: Postmortem human brain studies. PARTICIPANTS: We studied 17 subjects with schizophrenia, 17 subjects with bipolar disorder, and 17 normal control subjects.
RESULTS: The density of all GAD(67) mRNA-containing neurons was decreased by 53% and 28%, in layers 2 and 5, respectively, in subjects with schizophrenia, whereas in subjects with bipolar disorder there was a 35% reduction in layer 2 only. For GAD(67) mRNA-containing neurons that co-expressed NR(2A)mRNA, their numerical density was decreased by 73% and 52%, in layers 2 and 5, respectively, in subjects with schizophrenia and by 60% in layer 2 in those with bipolar disorder. In the schizophrenia group, the density of the GAD(67)mRNA-containing neurons that did not co-express NR(2A)mRNA was also decreased by 42% in layer 2. In both disease groups, the expression level of NR(2A)mRNA in GAD(67) mRNA-containing cells was unaltered.
CONCLUSIONS: The density of gamma-aminobutyric acid interneurons that express the NMDA NR(2A)subunit appears to be decreased in schizophrenia and bipolar disorder. Future studies will address whether subpopulations of these neurons may be differentially affected in the 2 conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15237077     DOI: 10.1001/archpsyc.61.7.649

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  151 in total

Review 1.  The contribution of GABAergic dysfunction to neurodevelopmental disorders.

Authors:  Kartik Ramamoorthi; Yingxi Lin
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

2.  Neural synchrony indexes disordered perception and cognition in schizophrenia.

Authors:  Kevin M Spencer; Paul G Nestor; Ruth Perlmutter; Margaret A Niznikiewicz; Meredith C Klump; Melissa Frumin; Martha E Shenton; Robert W McCarley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

3.  NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus.

Authors:  Yuchun Zhang; Takashi Yoshida; Donald B Katz; John E Lisman
Journal:  J Neurophysiol       Date:  2012-03-14       Impact factor: 2.714

4.  Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region.

Authors:  Alice Y Wang; Kathryn M Lohmann; C Kevin Yang; Eric I Zimmerman; Harry Pantazopoulos; Nicole Herring; Sabina Berretta; Stephan Heckers; Christine Konradi
Journal:  Acta Neuropathol       Date:  2011-10-04       Impact factor: 17.088

Review 5.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

Review 6.  The Functional and Molecular Properties, Physiological Functions, and Pathophysiological Roles of GluN2A in the Central Nervous System.

Authors:  Yongjun Sun; Xiaokun Cheng; Linan Zhang; Jie Hu; You Chen; Liying Zhan; Zibin Gao
Journal:  Mol Neurobiol       Date:  2016-01-21       Impact factor: 5.590

7.  Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.

Authors:  E Dong; R C Agis-Balboa; M V Simonini; D R Grayson; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

Review 8.  Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies.

Authors:  Ana D Stan; David A Lewis
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

10.  Response suppression deficits in treatment-naïve first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression.

Authors:  Margret S H Harris; James L Reilly; Michael E Thase; Matcheri S Keshavan; John A Sweeney
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.